Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 21,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
Interventions: Lenalidomide and Rituximab; Drug
Lead sponsor: Chronic Lymphocytic Leukemia Research Consortium; Network
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Bendamustine, Melphalan; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Maintenance Phase Intervention; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors, Lymphoma
Interventions: VTX-2337; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: InsuPatch; Device
Lead sponsor: Insuline Medical Ltd.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Progressive Pulmonary Fibrosis
Interventions: BMS-986278, BMS-986278 Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more

Conditions: Asthma, Allergies
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 20 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 65
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more

Conditions: Asthma, Wheezing
Interventions: daily fluticasone propionate, Montelukast, as-needed fluticasone propionate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Months to 59 Months
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 9 more

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Lung Cancer, Ovarian Cancer, Breast Cancer, Hodgkin's Disease, Neuroblastoma
Interventions: Symptom Assessment Scale; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Solid Tumors, Lymphoma, Malignancy
Interventions: Debio 1143 (AT-406); Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Fluorouracil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more

Conditions: Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions: B244 suspension, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tustin, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: GA Depot, Placebo; Drug · Other
Lead sponsor: Mapi Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more

Conditions: Arthritis, Rheumatoid Arthritis
Interventions: CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate; Biological · Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: BT062; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: Tenofovir 1% vaginal gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ridgefield, Connecticut

Conditions: HIV Infections, Opioid Use Disorder
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif, Tecfidera; Drug
Lead sponsor: IMS HEALTH GmbH & Co. OHG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: epoetin alfa; Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more

Conditions: Asthma
Interventions: Home Based Asthma Education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Helping Chicago's Westside Adults Breathe and Thrive

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

Pediatric Diabetics Type 1 Using InsuPatch

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

Individualized Therapy For Asthma in Toddlers

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Infectious Disease (ID) Testing OUtreach in Carceral Hubs

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Reducing Asthma Morbidity In High Risk Minority Preschool Children